Business Segments · Operating Income (Loss), Adjusted
MedSurg — Operating Income (Loss), Adjusted
Boston Scientific MedSurg — Operating Income (Loss), Adjusted decreased by 7.3% to $533M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.6%, from $536M to $533M. Over 3 years (FY 2022 to FY 2025), MedSurg — Operating Income (Loss), Adjusted shows an upward trend with a 15.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase indicates improved core profitability and operational leverage within the segment.
Detailed definition
Measures the profitability of the MedSurg segment by excluding non-recurring items, restructuring charges, and other adj...
Peer comparison
Commonly referred to as 'Adjusted Segment Operating Profit' or 'Segment EBIT' among medical device peers.
Metric ID:
bsx_segment_medsurg_operating_income_loss_adjustedHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $372.25M | $372.25M | $372.25M | $372.25M | $468M | $468M | $468M | $468M | $485M | $522M | $518M | $563M | $536M | $599M | $566M | $575M | $533M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +25.7% | +0.0% | +0.0% | +0.0% | +3.6% | +7.6% | -0.8% | +8.7% | -4.8% | +11.8% | -5.5% | +1.6% | -7.3% |
| YoY Change | — | — | — | — | +25.7% | +25.7% | +25.7% | +25.7% | +3.6% | +11.5% | +10.7% | +20.3% | +10.5% | +14.8% | +9.3% | +2.1% | -0.6% |
Range$372.25M – $599M
CAGR+9.4%
Avg YoY Growth+14.2%
Median YoY Growth+11.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's medsurg — operating income (loss), adjusted?
- Boston Scientific (BSX) reported medsurg — operating income (loss), adjusted of $533M in Q1 2026.
- How has Boston Scientific's medsurg — operating income (loss), adjusted changed year-over-year?
- Boston Scientific's medsurg — operating income (loss), adjusted decreased by 0.6% year-over-year, from $536M to $533M.
- What is the long-term trend for Boston Scientific's medsurg — operating income (loss), adjusted?
- Over 3 years (2022 to 2025), Boston Scientific's medsurg — operating income (loss), adjusted has grown at a 15.2% compound annual growth rate (CAGR), from $1.49B to $2.28B.
- What does medsurg — operating income (loss), adjusted mean?
- The core operating profit of the MedSurg segment, excluding one-time or non-operational charges.